AGING WITH HEMOPHILIA: THE CHALLENGE OF APPROPRIATE DRUG PRESCRIPTION Hemophilia and aging

Main Article Content

Pier Mannuccio Mannucci *
(*) Corresponding Author:
Pier Mannuccio Mannucci | piermannuccio.mannucci@policlinico.mi.it

Abstract

In high-income countries persons with severe hemophilia (PWH) A and B are aging, like their age-matched peers without hemophilia from the general population. Aging is associated not only with the comorbidities stemming from their inherited bleeding disorder (arthropathy, chronic viral infections such as hepatitis and AIDS) but also with the multiple chronic ailments associated with aging (cancer, cardiovascular disease, COPD).  Multimorbidity is inevitably associated with polypharmacy, i.e., the chronic daily intake of at least five drugs, and with the related risk of severe adverse events associated with the use of inappropriate drugs and drug-drug interactions. Information on the pattern of drug prescription and usage by PWH is relatively scanty, but on the whole, the available data indicate that the rate of polypharmacy, as well as the risk of drug-drug interaction, is relatively low in PWH and better than that in their age peers without hemophilia followed by general practitioners. It is believed that this advantage results from the collaborative coordination on drug prescribing exerted, through their integration with practitioners and organ specialists, by specialized hemophilia treatment centers in the frame of comprehensive care programs. However, the available cross-sectional data were mainly obtained in relatively young PWH, so that there is a need to obtain more accurate data from the ongoing prospective studies that are being carried out in more and more progressively aging PWH.


 


 Keywords: Hemophilia; Aging; Comorbidity; Drugs Interaction.


 


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

1. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1684-735.
2. Mannucci PM. Miracle of haemophilia drugs: Personal views about a few main players. Haemophilia. 2018;24:557-62.
3. Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost. 2006;4:510-6.
4. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815-25.
5. Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM; US Hemophilia Treatment Center Network. Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood. 2016;127:3073-81.
6. Philipp C. The aging patient with hemophilia: complications, comorbidities, and management issues. Hematology Am Soc Hematol Educ Program. 2010;2010:191-6.
7. Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia: contemporary concerns. Semin Hematol. 2016;53:35-9.
8. Mannucci PM, Iacobelli M. Progress in the contemporary management of hemophilia: The new issue of patient aging. Eur J Intern Med. 2017;43:16-21.
9. Kulkarni R, Soucie JM, Evatt BL; Hemophilia Surveillance System Project Investigators. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol. 2005;79:36-42.
10. Siboni SM, Mannucci PM, Gringeri A, Franchini M, Tagliaferri A, Ferretti M, Tradati FC, Santagostino E, von Mackensen S; Italian Association of Haemophilia Centres (AICE). Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost. 2009;7:780-6.
11. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol. 2010;148:522-33.
12. Fransen van de Putte DE, Fischer K, Pulles AE, Roosendaal G, Biesma DH, Schutgens RE, Mauser-Bunschoten EP. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res. 2012;130:157-62.
13. Ording AG, Sørensen HT. Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogs. Clin Epidemiol. 2013;5:199-203.
14. Zwiers M, Lefrandt JD, Mulder DJ, Smit AJ, Gans RO, Vliegenthart R, Brands-Nijenhuis AV, Kluin-Nelemans JC, Meijer K. Coronary artery calcification score and carotid intima–media thickness in patients with hemophilia. J Thromb Haemost. 2012;10:23-9.
15. Tuinenburg A, Rutten A, Kavousi M, Leebeek FW, Ypma PF, Laros-van Gorkom BA, Nijziel MR, Kamphuisen PW, Mauser-Bunschoten EP, Roosendaal G, Biesma DH, van der Lugt A, Hofman A, Witteman JC, Bots ML, Schutgens RE. Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:799-804.
16. Biere-Rafi S, Baarslag MA, Peters M, Kruip MJ, Kraaijenhagen RA, Den Heijer M, Büller HR, Kamphuisen PW. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost. 2011;105:274-8.
17. Fransen van de Putte DE, Fischer K, Makris M, Tait RC, Chowdary P, Collins PW, Meijer K, Roosendaal G, Schutgens RE, Mauser-Bunschoten EP. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thromb Haemost. 2013;109:16-23.
18. Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA. A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Adv. 2018;2:1325-33.
19. Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P; ADVANCE Working Group. Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe. Haemophilia. 2016;22:248-55.
20. Franchini M, Lippi G, Montagnana M, Targher G, Zaffanello M, Salvagno GL, Rivolta GF, Perna CD, Tagliaferri A. Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev. 2009;35:374-7.
21. Astermark J, Makris M, Mauser-Bunschoten E, Nemes L, D'oiron R, Oldenburg J, Ingerslev J; Malignancy in Haemophilia Workshop Group. Malignant disease in the haemophilic population: moving towards a management consensus? Haemophilia. 2012;18:664-71.
22. Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Iorio A, Mannucci PM. Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. Haemophilia. 2018;24:e6-e10.
23. Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A. Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls. Haemophilia. 2018;24:726-32.
24. Staritz P, de Moerloose P, Schutgens R, Dolan G; ADVANCE Working Group. Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group. Haemophilia. 2013;19:833-40.
25. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood. 2009;114:5256-63.
26. Schutgens RE, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser-Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia. 2009;15:952-8.
27. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345-51.
28. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57-65.
29. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870-4.
30. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170:1648-54.
31. Carroll C, Hassanin A. Polypharmacy in the elderly-when good drugs lead to bad outcomes: a teachable moment. JAMA Intern Med. 2017;177:871.
32. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc. 2017;57:729-38.
33. Riva S, Mancuso ME, Cortesi L, Nobili A, Santagostino E, Peyvandi F, Mannucci PM. Polypharmacy in older adults with severe haemophilia. Haemophilia. 2018;24:e1-e3.
34. Boccalandro E, Mancuso ME, Riva S, Pisaniello DM, Ronchetti F, Santagostino E, Peyvandi F, Solimeno LP, Mannucci PM, Pasta G. Ageing successfully with haemophilia: A multidisciplinary programme. Haemophilia. 2018;24:57-62.
35. Giangrande PLF, Peyvandi F, O'Mahony B, Behr-Gross ME, Hilger A, Schramm W, Mannucci PM. Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia. 2017;23:370-5.
36. Grumbach K. Chronic illness, comorbidities, and the need for medical generalism. Ann Fam Med. 2003;1:4-7.